GB2312674A — Tetrahydroquinoline inhibitors of trypsin and thrombin
Assigned to Novartis AG · Expires 1997-11-05 · 29y expired
What this patent protects
Compounds of the general formula I in which A and B are hydrogen, a C 1 -C 5 alkyl which may be interrupted by one or more oxygen atoms, C 1 -C 5 alkenyl, alkoxyalkyl, hydroxyalkyl, alkylthioalkyl, alkylamino, dialkylamino or trialkylamino, or together form a methylene group, or…
USPTO Abstract
Compounds of the general formula I in which A and B are hydrogen, a C 1 -C 5 alkyl which may be interrupted by one or more oxygen atoms, C 1 -C 5 alkenyl, alkoxyalkyl, hydroxyalkyl, alkylthioalkyl, alkylamino, dialkylamino or trialkylamino, or together form a methylene group, or together with the carbon atom to which they are attached form a C 3 -C 7 carbocylic ring; and C is a group -R-X in which R is a C 1 -C 4 alkylene group optionally interrupted by oxygen or is a direct bond and X is an aminocarbonyl, carbonylamino, sulfonylamino, amino, azido or heterocyclic alkyl, or salts thereof are inhibitors of trypsin and thrombin. Novel intermediates have the formula
Drugs covered by this patent
- Beleodaq (belinostat) · Acrotech Biopharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.